Citations

Clear

4610 citation(s) found for "Lu, Brian".

Blocking the NOTCH Pathway Inhibits Vascular Inflammation in Large-Vessel Vasculitis
Piggott, Kisha , Deng, Jiusheng , Warrington, Kenneth J. , Younge, Brian R., Kubo, Jessica, Goronzy, Jörg J. , Weyand, Cornelia M. , Desai, Manisha , Warrington, Kenneth J , Goronzy, Jorg

Mayo Clinic

Circulation | January 11, 2011 | Volume: 123 | Issue: 3 | Pages: 309-318

10.1161/circulationaha.110.936203 | PMID 21220737 Get It

Background— Giant cell arteritis is a granulomatous vasculitis of the aorta and its branches that causes blindness, stroke, and aortic aneurysm. CD4 T cells are key pathogenic regulators, instructed by vessel wall dendritic cells to differentiate into vasculitic T cells. The unique pathways driving this dendritic cell–T-cell interaction are incompletely understood, but may provide novel therapeutic targets for a disease in which the only established therapy is long-term treatment with high doses of corticosteroids. Methods and Results— Immunohistochemical and gene expression analyses of giant cell arteritis-affected temporal arteries revealed abundant expression of the NOTCH receptor and its ligands, Jagged1 and Delta1. Cleavage of the NOTCH intracellular domain in wall-infiltrating T cells indicated ongoing NOTCH pathway activation in large-vessel vasculitis. NOTCH activation did not occur in small-vessel vasculitis affecting branches of the vasa vasorum tree. We devised 2 strategies to block NOTCH pathway activation: γ-secretase inhibitor treatment, preventing nuclear translocation of the NOTCH intracellular domain, and competing for receptor-ligand interactions through excess soluble ligand, Jagged1-Fc. In a humanized mouse model, NOTCH pathway disruption had strong immunosuppressive effects, inhibiting T-cell activation in the early and established phases of vascular inflammation. NOTCH inhibition was particularly effective in downregulating Th17 responses, but also markedly suppressed Th1 responses. Conclusions— Blocking NOTCH signaling depleted T cells from the vascular infiltrates, implicating NOTCH- NOTCH ligand interactions in regulating T-cell retention and survival in vessel wall inflammation. Modulating the NOTCH signaling cascade emerges as a promising new strategy for immunosuppressive therapy of large-vessel vasculitis.
Reflections on the contributions of Harvey Cushing to the surgery of peripheral nerves
Tubbs, R. Shane , Patel, Neal , Nahed, Brian V. , Cohen‐Gadol, Aaron , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 7, 2011 | Volume: 114 | Issue: 5 | Pages: 1442-1448

10.3171/2010.11.jns10804 | PMID 21214330 Get It

By the time Harvey Cushing entered medical school, nerve reconstruction techniques had been developed, but peripheral nerve surgery was still in its infancy. As an assistant surgical resident influenced by Dr. William Halsted, Cushing wrote a series of reports on the use of cocaine for nerve blocks. Following his residency training and a hiatus to further his clinical interests and intellectual curiosity, he traveled to Europe and met with a variety of surgeons, physiologists, and scientists, who likely laid the groundwork for Cushing's increased interest in peripheral nerve surgery. Returning to The Johns Hopkins Hospital in 1901, he began documenting these surgeries. Patient records preserved at Yale's Cushing Brain Tumor Registry describe Cushing's repair of ulnar and radial nerves, as well as his exploration of the brachial plexus for nerve repair or reconstruction. The authors reviewed Harvey Cushing's cases and provide 3 case illustrations not previously reported by Cushing involving neurolysis, nerve repair, and neurotization. Additionally, Cushing's experience with facial nerve neurotization is reviewed. The history, physical examination, and operative notes shed light on Cushing's diagnosis, strategy, technique, and hence, his surgery on peripheral nerve injury. These contributions complement others he made to surgery of the peripheral nervous system dealing with nerve pain, entrapment, and tumor.
Are e-Health Web Users Looking for Different Symptom Information Than Callers to Triage Centers?
North, Frederick , Varkey, Prathibha, Laing, Brian Yoshio, Cha, Steven S., Tulledge‐Scheitel, Sidna M. , Cha, Steven S.

Mayo Clinic

Telemedicine and e-Health | January 7, 2011 | Volume: 17 | Issue: 1 | Pages: 19-24

10.1089/tmj.2010.0120 | PMID 21214306 Get It

Introduction: Telemedicine options for symptom assessment include both telephonic means (call centers) and Internet sites. Although symptom assessment call centers have been available for decades, symptom assessment over the Internet is relatively new. It is not well known what types of symptoms Internet users are seeking assessment for and whether extant telephone triage algorithms would be applicable to Internet users. Methods: Symptom assessments on a heavily used Internet site ( MayoClinic.com ) were compared with symptom calls to a U.S. call center (Ask Mayo Clinic). Results: Internet users sought symptom assessments about adult symptoms 13 times more often than children's symptoms. In contrast, over the telephone, adult symptoms were addressed 2.1 times more frequently than children's symptoms. Despite the differences in frequencies of adult and child symptom assessments, users of the Internet and telephone callers asked about specific symptoms with similar relative frequencies. Analysis of 20 adult symptom types shared by the Web and call center revealed that by excluding only 2 assessments (nasal symptoms and leg pain) the remaining 18 showed a significant correlation in counts of use ( r 2 = 0.68, p < 0.001 for linear trend). Conclusions: Internet users have symptoms assessed in similar proportions to callers, with a few exceptions. Compared with callers, Web users are much more likely looking for information about adult symptoms. Callers are proportionally asking more about acute symptoms, whereas Internet users appear more interested in symptom assessment of chronic conditions.
Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703.
Ramaswamy, B, Cohen, Brian E., Pellegrino, C., Hershman, DL, Chuang, Emil , Somlo, George, Swaby, Ramona F., Hopkins, Una, Christos, PJ, Espinoza‐Delgado, Igor, Sparano, JA, Bhalla, Kapil N. , Goetz, Matthew Bidwell

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 2_Supplement | Pages: 404

10.1158/0008-5472.sabcs-404 Get It

Abstract Abstract #404 Background: The oral HDACi vorinostat (V) sensitizes breast cancer cells to tubulin polymerizing agents and anti-VEGF directed therapies in vitro. We sought to determine the safety and efficacy of V plus paclitaxel (P) and bevacizumab (B) as first-line therapy for MBC.&#x2028; Methods: Eligible patients (pts) with measurable disease, ECOG PS 0 or 1, and no prior chemotherapy for MBC, received P (90mg/m2) on days 1, 8, 15 and B (10mg/kg) on days 1,15 every 28 days, plus V 200 mg (N=3) or 300 mg (N=28) BID orally for 3 days given the day before, day of, and day after each P dose. Response was assessed after every 3 cycles (RECIST). The trial was designed to distinguish between a response rate of &lt; 40% vs. &gt; 60% (alpha=0.10, beta=0.10) using Simon's optimal 2-stage design. At least 12 responses were required in the first 28 evaluable pts in the 1st stage and 21 of 41 in the 2nd stage.&#x2028; Results: There were no dose-limiting toxicities among the first 6 pts treated at the 1st (200 mg BID; N=3) and 2nd (300 mg BID; N=3) dose levels. Among the 26 evaluable pts treated at the recommended phase II dose of 300mg bid in the 1st stage, 14 patients had a partial response (PR-54%; 90% confidence interval [C.I.] 36%-71%), 6 had stable disease (SD) at 3 months and remain on treatment, 2 had SD as the best response with progressive disease (PD) at 11.8 and 15 months, and 4 had PD as their best response. Additionally, 2 of 3 pts treated at the first V dose level had a PR, indicating PR in 16 of 29 overall (55%, 90% C.I 38%-71%). Only 11 of 29 evaluable pts (38%) have progressed after a median followup of 10.5 months (R-2.3-14.9). Two pts had tumor biopsies and peripheral blood mononuclear cells (PBMC) collected before and 4 hours after the 3rd V dose (300 mg BID) which showed increased acetylation of K69 lysine residue of the chaperone protein Hsp 90, upregulation of Hsp70, and downregulation of AKT by Western Blot, providing evidence of Hsp90 inhibition in tumor and PBMC.&#x2028; &#x2028; Gr 3-4 toxicities included neutropenia (26%), neuropathy (23%), fatigue (16%), thrombosis (10%), vomiting (6%), hypertension (3%), and diarrhea (3%).&#x2028; Conclusions: Our preliminary findings indicate that the HDACi V inhibits Hsp90 and downregulates AKT in breast cancer in vivo, and enhances the effectiveness of P plus B in MBC. Accrual is nearly complete and the final efficacy analysis will be presented. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 404.
Comparison of Cold and Warm Ischemia During Partial Nephrectomy in 660 Solitary Kidneys Reveals Predominant Role of Nonmodifiable Factors in Determining Ultimate Renal Function
Lane, Brian R. , Russo, Paul , Uzzo, Robert G. , Hernández, Adrían V. , Boorjian, Stephen A. , Thompson, R. Houston, Fergany, Amr, Love, Thomas E. , Campbell, Steven C.

Mayo Clinic

Journal of Urology | December 18, 2010 | Volume: 185 | Issue: 2 | Pages: 421-427

10.1016/j.juro.2010.09.131 | PMID 21167524 Get It

Do subtle cortical structure changes indicate a developmental basis for temporal lobe epilepsy?
Roper, Steven N. , Moseley, Brian D. , Cascino, Gregory D.

Mayo Clinic

Neurology | December 9, 2010 | Volume: 76 | Issue: 2 | Pages: 117-118

10.1212/wnl.0b013e318205d545 | PMID 21148115 Get It

Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL
Rabe, Kari G. , Achenbach, Sara J., Vachon, Celine M. , Goldin, Lynn R. , Strom, Sara S., Lanasa, Mark C., Spector, Logan G. , Rassenti, Laura Z., Leis, José F., Camp, Nicola J. , Glenn, Martha, Cunningham, Julie M. , Hanson, Curtis A. , Marti, Gerald E., Weinberg, J. Brice , Morrison, Vicki A., Link, Brian K. , Call, Timothy G. , Caporaso, Neil E., Cerhan, James R. , Slager, Susan L. , Vachon, Celine M. , Kay, Neil E. , Chaffee, Kari G. , Cerhan, James R , Link, Brian K

Mayo Clinic

Blood | December 3, 2010 | Volume: 117 | Issue: 6 | Pages: 1911-1916

10.1182/blood-2010-09-308205 | PMID 21131588 Get It

Abstract Prior genome-wide association (GWA) studies have identified 10 susceptibility loci for risk of chronic lymphocytic leukemia (CLL). To identify additional loci, we performed a GWA study in 407 CLL cases (of which 102 had a family history of CLL) and 296 controls. Moreover, given the strong familial risk of CLL, we further subset our GWA analysis to the CLL cases with a family history of CLL to identify loci specific to these familial CLL cases. Our top hits from these analyses were evaluated in an additional sample of 252 familial CLL cases and 965 controls. Using all available data, we identified and confirmed an independent association of 4 single-nucleotide polymorphisms (SNPs) that met genome-wide statistical significance within the IRF8 (interferon regulatory factor 8) gene (combined P values ≤ 3.37 × 10−8), located in the previously identified 16q24.1 locus. Subsetting to familial CLL cases, we identified and confirmed a new locus on chromosome 6p21.3 (combined P value = 6.92 × 10−9). This novel region harbors the HLA-DQA1 and HLA-DRB5 genes. Finally, we evaluated the 10 previously reported SNPs in the overall sample and replicated 8 of them. Our findings support the hypothesis that familial CLL cases have additional genetic variants not seen in sporadic CLL. Additional loci among familial CLL cases may be identified through larger studies.
Approach to acute or subacute myelopathy
Schmalstieg, William F., Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Neurology | November 4, 2010 | Volume: 75 | Issue: 18_supplement_1 | Pages: No page available

10.1212/wnl.0b013e3181fb3638 | PMID 21041766 Get It

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
Maurer, Matthew J. , Allmer, Cristine, Rabe, Kari G. , Weiner, George J. , Call, Timothy G. , Link, Brian K. , Hanson, Curtis A. , Cerhan, James R. , Shanafelt, Tait D. , Drake, Matthew T. , Slager, Susan L. , Zent, Clive S. , Kay, Neil E. , Witzig, Thomas E. , Chaffee, Kari G. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Mayo Clinic

Blood | November 3, 2010 | Volume: 117 | Issue: 5 | Pages: 1492-1498

10.1182/blood-2010-07-295683 | PMID 21048153 Get It

Abstract Vitamin D insufficiency is common globally and low levels are linked to higher cancer incidence. Although vitamin D insufficiency is related to inferior prognosis in some cancers, no data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We evaluated the relationship of 25(OH)D serum levels with time-to-treatment (TTT) and overall survival (OS) in newly diagnosed CLL patients participating in a prospective cohort study (discovery cohort) and a separate cohort of previously untreated patients participating in an observational study (confirmation cohort). Of 390 CLL patients in the discovery cohort, 119 (30.5%) were 25(OH)D insufficient. After a median follow-up of 3 years, TTT (hazard ratio[HR] = 1.66; P = .005) and OS (HR = 2.39; P = .01) were shorter for 25(OH)D-insufficient patients. In the validation cohort, 61 of 153 patients (39.9%) were 25(OH)D insufficient. After a median follow-up of 9.9 years, TTT (HR = 1.59; P = .05) and OS (HR 1.63; P = .06) were again shorter for 25(OH)D-insufficient patients. On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, Rai stage, CD38 status, ZAP-70 status, immunoglobulin heavy chain variable (IGHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing, 25(OH)D insufficiency remained an independent predictor of TTT (HR = 1.47; P = .008), although the association with OS was not significant (HR = 1.47; P = .07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing.